Meet the Team
A world leading team of experts with extensive scientific and clinical experience in antibiotics, mixed with entrepreneurial thinking and a strong business sense. Our passion is to fight superbugs to positively impact peoples lives, and we do this in a dynamic and fun workplace. BioVersys featured in a recent video highlighting the fight against AMR in Basel.
Dr. Marc Gitzinger
Marc is Chief Executive Officer and co-founder of BioVersys. He has over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset early clinical stage company. These assets address significant unmet medical needs in infectious disease such as tuberculosis and hospital acquired Acinetobacter infections. He has raised over $30 million in equity financing and established several important partnerships with a big pharma and other R&D organizations. Marc is a multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. He is also vice-president of the board of the BEAM Alliance, a European association representing over 60 European and international SMEs active in antimicrobial research and development and board member of the AMR Industry Alliance. Marc is a thought leader in the field of antimicrobial research and development, passionate about next generation antimicrobial therapies. He leads a highly motivated team striving to bring life-saving antimicrobial therapies to patients. Marc is co-author on several high ranked scientific publications and patents in the field.
Dr. Sergio Lociuro
Sergio is Chief Scientific Officer of BioVersys. His background spans from early drug discovery to early clinical development. He has conducted Phase I clinical studies, participated in later clinical studies and discussions with both the US FDA and EMA. He received his Laurea degree in Chemistry at the University of Rome, Italy in 1981 and, after a two-year postdoctoral fellowship at the Italian Research National Council, he moved to UNB, Canada, where he received his Ph.D in 1987. In the same year he started his career in the pharmaceutical industry as a medicinal chemist. In his almost 30 years’ experience in major pharmaceutical companies and SMEs, Sergio has held positions such as Director of Medicinal Chemistry and International Project Leader in GSK, Head of Peptide Epitope Mimetics in Polyphor Ltd and Head of Research and Scientific Communication in Arpida AG and has been part of the Board of Directors of Arpida A/S. As the founder of THOT consulting Sagl, a Swiss consulting firm, Sergio provided services in the Research and Development of anti-infectives and pharmaceutical drugs in general. He has held the position of CSO in C10 Pharma and Adenium Biotech, two Scandinavian biotech companies. Sergio has published extensively throughout his career and is co-author on high ranked scientific publications and patents in the field.
Dr. Glenn Dale
Glenn is Chief Development Officer of BioVersys. He is a distinguished expert in infectious diseases, the author of numerous publications, and inventor on many patents. Since February 2019 Glenn has led the clinical development activities at BioVersys, applying his 25 years of R&D experience and significant knowledge in the modern development of antibiotics. Glenn obtained his Ph.D. in Biochemistry in 1993 from the University of Basel. Following post-doctoral studies in Basel he has held the following positions; Group Leader at Roche, Head of Biology, Site Head at Morphochem AG and Scientific Coordinator responsible for pre-clinical research at Arpida. In 2009 he joined Polyphor where he led the Antibiotic Research and Early Development, successfully transitioning Murepavadin (POL7080) from pre-clinical activities to Phase 3 studies. Glenn is an expert in developing and implementing modern antibiotic clinical development plans (e.g. devising pathogen specific development) and is experienced in presenting to and discussing with European and US regulatory authorities, e.g. scientific advice meetings (MHRA, EMA), Type C meetings (FDA) and End of Phase 2 meeting (FDA).
Dr. Jonathan James Butcher
Jonathan joined BioVersys in May 2018 and leads the business development activities with passion and dedication. Within a short time, Jonathan impacted the business of BioVersys with in-licensing and acquisition deals, while leading the non-dilutive fund-raising activities that resulted in European Union IMI and CARB-X awards. Jonathan also supports the company’s capital fund-rising activities. Prior to BioVersys he was Head of Business Development for Polyphor’s Drug Discovery Unit, where he secured drug discovery collaboration & licensing deals with leading global pharmaceutical and biotech companies. At Polyphor he also led the valuation of Polyphor’s pipeline assets, Murepavidin (POL7080) - Phase III Pseudomonas aeruginosa selective antibiotic, licensed to Roche in 2013, US$547 million and POL6014 - Phase Ib selective elastase inhibitor for respiratory diseases, licensed to Santhera in 2018, US$130 million. Prior to Polyphor, Jonathan led Hit-2-Lead and medicinal chemistry projects at Evotec, UK. Jonathan obtained his Ph.D. in organic chemistry from the University of Reading, England and is the co-author on a number of scientific publications and patents.
Dr. Beat Kiser
Beat is a finance executive with over 30 years experience in multinational as well as smaller companies in the pharmaceutical and chemical industry. He has worked over 10 years in Asia. Beat has a Ph.D. in economics/business administration from University of Zurich.
Dr. Marilyne Bourotte
Marilyne obtained her Ph.D. in Medicinal Chemistry from the University of Pharmacy, Strasbourg, France and has 10-year experience in medicinal chemistry, leading diverse programs from hit-to-lead to preclinical candidate selection. She is based at BioVersys SAS at the Institut Pasteur de Lille and leads BioVersys’ Medicinal Chemistry activities.
Dr. Olivier Defert
Olivier received his PhD in chemistry from the faculty of Pharmacy of Lille in 2005 while already working at DevGen in Belgium since 2000 where he was medicinal chemist and then section leader for more than 8 years, with responsibilities in combinatorial and medicinal chemistry as well as in regulatory preclinical development. Subsequently to the company’s restructuration, he co-founded with Dr. Dirk Leysen, Amakem NV, a medtech company in Belgium focused on soft kinase inhibitors for multiple therapeutic applications where he managed the medicinal chemistry group and the non-clinical development of AMA0076 (now PHP-201, Sovesudil, entering Phase 3 in Asia), a novel soft ROCK inhibitor for the treatment of glaucoma (acquired in 2016 by pH Pharma Inc.). Between 2016 and 2021, he served as a consultant to different medtech / biotech companies in the field of CMC, (medicinal) chemistry and preclinical development, including Tarsius Pharma in Israel as VP R&D. He is co-inventor of > 20 patents and co-author of 9 peer reviewed publications. Olivier joined BioVersys SAS in Lille in March 2021 as Head of Research and external partnerships.
Alina is the Executive Assistant to the CEO. She has significant experience at being the right hand of executive leaders. She is a new generation business partner.
Dr. Michel Pieren
Michel obtained holds a Ph.D. in biochemistry from the ETH Zurich and has 10 years of industry experience at BioVersys in leading scientific staff and cross functional projects teams in research and preclinical development. When he joined BioVersys he guided the further development of the TRIC-technology platform.
Dr. Christian Kemmer
Christian is Clinical Project Manager and Project Leader at BioVersys AG. His background spans from early drug discovery to clinical development. Christian studied biology and biotechnology in Germany and Finland and received his PhD from ETH Zurich in 2010. After a postdoctoral fellowship in the Pharma Research and Early Development (pRED) division at F. Hoffmann-La Roche in Basel he joined BioVersys in 2014 as a laboratory manager, being responsible for the in-house research activities around Gram-negative bacteria and tuberculosis and the coordination of external collaborations. In the last years, Christian developed into different positions along the R&D activities of BioVersys and transitioned into the preclinical project leader role in 2018. In 2020, Christian was promoted into his current role as clinical project manager being responsible for the BV100 clinical development program. He is also lead-ing scientist and project coordinator of the international Eurostars Impact2 consortium. Christian has published extensively in the recent years and is also co-author on multiple high-impact scientific publications and patents.
Dr. Vincent Trebosc
Vincent holds a Marie Sklodowska-Curie PhD in Microbiolgy from a joint program of BioVersys and the University of Basel. He worked as Research Scientist for two years and he currently is laboratory Head at BioVersys.
Dr. Alessia Michelotti
Alessia is an Organic Chemistry master's graduate from the University of Turin, Italy and obtained her Ph.D from Paris-Saclay University in collaboration with CortecNet SAS through the Marie-Sklodowska Curie scholarship. She is based at BioVersys SAS at the Institut Pasteur de Lille, and is a research scientist developing new anti-infective agents.
Alexia is an Organic Chemistry master's graduate from the University of Lille, France. She is based at BioVersys SAS at the Institut Pasteur de Lille and is a high-level technician developing new anti-infective agents.
Dr. Zainab Edoo
Zainab has a PhD in Biochemistry from Sorbonne Université, Paris. She is based in Dr Alain Baulard's team at the Institut Pasteur de Lille. Her role is to obtain in vitro microbiological data to assist the clinical development of a booster compound of the anti-tuberculosis drug, ethionamide.